
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Cultured, Autologous Hair Follicle Cell
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : InnovaCell Biotechnologie
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RCS-01 is a patient-specific cell therapy in development to regenerate the extracellular tissue matrix under aging or sun-damaged skin characterized by fine wrinkles and loss collagen structure.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
November 09, 2021
Lead Product(s) : Cultured, Autologous Hair Follicle Cell
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : InnovaCell Biotechnologie
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : RCS-01
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : JensonR+ | PHARMALOG Institute | Syreon Corporation | Innovacell Biotechnologie | Datinf GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Intradermal Injections of RCS-01 in Male and Female Subjects
Details : RCS-01 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Skin Aging.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
March 18, 2015
Lead Product(s) : RCS-01
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : JensonR+ | PHARMALOG Institute | Syreon Corporation | Innovacell Biotechnologie | Datinf GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : RCT-01
Therapeutic Area : Musculoskeletal
Study Phase : Phase I/ Phase II
Sponsor : Syreon Corporation | Innovacell Biotechnologie
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Efficacy of RCT-01 in Men and Women With Unilateral, Chronic Achilles Tendinosis
Details : RCT-01 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Tendinopathy.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 01, 2015
Lead Product(s) : RCT-01
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I/ Phase II
Sponsor : Syreon Corporation | Innovacell Biotechnologie
Deal Size : Inapplicable
Deal Type : Inapplicable
